



Figure S1 Flow diagram of patient selection. SEER, Surveillance, Epidemiology, and End Results.

Table S1 Histopathology of PMCTs differentiate by the ICCC site recode extended ICD-0-3/WHO 2008

Sarcoma

- IX (d.8): Blood vessel tumors
- IX(e): Unspecified soft tissue sarcomas
- IX (d.6): Leiomyosarcomas
- IX (d.7): Synovial sarcomas
- IX (b.1): Fibroblastic and myofibroblastic tumors
- IX (d.11): Miscellaneous soft tissue sarcomas
- IX (a): Rhabdomyosarcomas
- IX (d.4): Liposarcomas
- IX (d.5): Fibrohistiocytic tumors

Lymphoma

- II (a): Hodgkin lymphomas
- II (b.1): Precursor cell lymphomas
- II (b.2): Mature B-cell lymphomas except Burkitt lymphoma
- II (b.3): Mature T-cell and NK-cell lymphomas
- II (b.4): Non-Hodgkin lymphomas, NOS
- II (c): Burkitt lymphoma
- II (d): Miscellaneous lymphoreticular neoplasms
- II (e): Unspecified lymphomas

Mesothelioma

Others

- III (c.2): PNET
- IV (b): Other peripheral nervous cell tumors
- I (e): Unspecified and other specified leukemias
- VII (b): Hepatic carcinomas
- VIII (d.2): Malignant chordomas
- X (b.2): Malignant teratomas: extracranial/extragenital
- X (b.4): Yolk sac tumor: extracranial/extragenital
- XI (f.10): Carcinomas of other specified sites
- XII (b): Other unspecified malignant tumors

Not classified by ICCC or *in situ*

PMCTs, primary malignant cardiac tumors; ICCC, International Classification of Childhood Cancer; WHO, World Health Organization.